Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 8/20 | 0.44 |
| ▸ | KLK7 | P49862 | 7/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.41 |
| ▸ | CDC25B | P30305 | 5/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.41 |
| ▸ | CDC25A | P30304 | 3/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26900852 | 1.00 | KLK5 (0.44) | KLK5KLK7PTPN1CDC25BPTPN2 | |
| SCHEMBL24256738 | 0.89 | KLK5 (0.51) | KLK5KLK7PTPN1CDC25BPTPN2 | |
| SCHEMBL24256425 | 0.89 | KLK5 (0.51) | KLK5KLK7PTPN1CDC25BPTPN2 | |
| SCHEMBL26879308 | 0.86 | KLK5 (0.41) | KLK5KLK7NAAA | |
| SCHEMBL29381580 | 0.85 | ALDH1A1 (0.46) | NAAATACR2NT5E | |
| SCHEMBL29384459 | 0.85 | ALDH1A1 (0.46) | NAAATACR2NT5E | |
| SCHEMBL26879067 | 0.82 | KLK5 (0.50) | KLK5KLK7PTPN1CDC25BPTPN2 | |
| SCHEMBL23705418 | 0.80 | ALDH1A1 (0.41) | KLK5KLK7PTPN1CDC25BPTPN2 | |
| SCHEMBL26900483 | 0.80 | ALDH1A1 (0.41) | KLK5KLK7PTPN1CDC25BPTPN2 | |
| SCHEMBL23705084 | 0.80 | TP53 (0.45) | KLK5KLK7PTPN1CDC25BPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | KLK5 3082/4885KLK7 2530/4885PTPN1 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.